These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1434 related articles for article (PubMed ID: 33956950)

  • 1. The peripheral and core regions of virus-host network of COVID-19.
    Wang B; Dong X; Hu J; Ma X; Han C; Wang Y; Gao L
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 33956950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactomes of SARS-CoV-2 and human coronaviruses reveal host factors potentially affecting pathogenesis.
    Chen Z; Wang C; Feng X; Nie L; Tang M; Zhang H; Xiong Y; Swisher SK; Srivastava M; Chen J
    EMBO J; 2021 Sep; 40(17):e107776. PubMed ID: 34232536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
    Das AB
    BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conserved Genomic Terminals of SARS-CoV-2 as Coevolving Functional Elements and Potential Therapeutic Targets.
    Chan AP; Choi Y; Schork NJ
    mSphere; 2020 Nov; 5(6):. PubMed ID: 33239366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiologies and therapeutic targets.
    Bellucci G; Ballerini C; Mechelli R; Bigi R; Rinaldi V; Reniè R; Buscarinu MC; Baranzini SE; Madireddy L; Matarese G; Salvetti M; Ristori G
    F1000Res; 2020; 9():992. PubMed ID: 33456761
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection.
    Mok DZL; Chan CYY; Ooi EE; Chan KR
    FEBS J; 2021 Sep; 288(17):5055-5070. PubMed ID: 33124149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
    Ting CT; Chen BS
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of human proteins and genes involved in SARS-CoV-2 infection.
    Jahanafrooz Z; Chen Z; Bao J; Li H; Lipworth L; Guo X
    Gene; 2022 Jan; 808():145963. PubMed ID: 34530086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing.
    Krishnamoorthy P; Raj AS; Roy S; Kumar NS; Kumar H
    Comput Biol Med; 2021 Jan; 128():104123. PubMed ID: 33260034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2-host proteome interactions for antiviral drug discovery.
    Liu X; Huuskonen S; Laitinen T; Redchuk T; Bogacheva M; Salokas K; Pöhner I; Öhman T; Tonduru AK; Hassinen A; Gawriyski L; Keskitalo S; Vartiainen MK; Pietiäinen V; Poso A; Varjosalo M
    Mol Syst Biol; 2021 Nov; 17(11):e10396. PubMed ID: 34709727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
    Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
    J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a special cell type as a determinant of the kidney tropism of SARS-CoV-2.
    Lin H; Ma X; Xiao F; Su H; Shi Y; Liu Y; Song L; Zhang Z; Zhang C; Peng H
    FEBS J; 2021 Sep; 288(17):5163-5178. PubMed ID: 34228902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.
    Glebov OO
    FEBS J; 2020 Sep; 287(17):3664-3671. PubMed ID: 32428379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing.
    Habibi M; Taheri G; Aghdam R
    Sci Rep; 2021 Apr; 11(1):9378. PubMed ID: 33931664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new insight into sex-specific non-coding RNAs and networks in response to SARS-CoV-2.
    Askari N; Hadizadeh M; Rashidifar M
    Infect Genet Evol; 2022 Jan; 97():105195. PubMed ID: 34954105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overlapping host pathways between SARS-CoV-2 and its potential copathogens: An in silico analysis.
    Vavougios GD
    Infect Genet Evol; 2020 Dec; 86():104602. PubMed ID: 33132111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triazavirin might be the new hope to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Hudecová IMJČGKMPL
    Ceska Slov Farm; 2021; 70(1):18-25. PubMed ID: 34237949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.